Tetra Bio-Pharma announced that the company’s investigational new drug involving cannabinoids, QIXLEEF, received guidance to strengthen its nonclinical and toxicological data from the U.S. Food and Drug Administration, which brings the aerosol botanical therapy closer to marketing approval.
Although the endocannabinoid system has been intensely studied, there are still few drugs approved or in development that interact with it.
California-based GW Pharmaceuticals initiated the company’s first U.S. Phase III trial studying nabiximols, which is known as Sativex outside the United States, as a potential treatment for multiple sclerosis-associated spasticity.
The medical cannabis market in the United States, even with all of its restrictions, continues to be a fertile area not only for dispensaries, but pharma companies developing cannabis-derived drugs; and proponents say further growth can be generated by educating physicians about medical cannabis.
Zynerba Pharmaceuticals’ experimental cannabis-based gel Zygel was not statistically significant in improving aberrant behavior when compared to a placebo in patients with a neurological disorder called Fragile X syndrome.
CURE Pharmaceutical, an innovative drug delivery and development company, signed an exclusive licensing agreement with ReLeaf Europe, one of Europe’s leading pharmaceutical groups specialized in medicinal cannabis products.
Researchers said Evidence is weak for whether medicinal cannabis treatments can relieve mental illnesses such as anxiety, depression and psychosis, and doctors should prescribe them with great caution.
Health investigators are casting a wide net to understand what is sickening hundreds of vapers across the United States and still have not ruled out any product on the market.
The Federal Trade Commission warned three companies selling products infused with cannabidiol that it was illegal to advertise that such products could fight disease without providing credible scientific evidence.
GW Pharmaceuticals’ marijuana-based treatment Epidyolex won a positive recommendation for marketing approval from a European Medicines Agency (EMA) panel for use as an additional treatment for two types of seizures.